Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Response assessment of NovoTTF-100A versus best physician's choice chemotherapy in recurrent glioblastoma.

Response assessment of NovoTTF-100A versus best physician's choice chemotherapy in recurrent glioblastoma. Cancer Med. 2014 Jun; 3(3):592-602.

View in: PubMed

Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.